A5039618415- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Potassium and Related Disorders
- Pulmonary Hypertension Research and Treatments
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- Mechanical Circulatory Support Devices
- Cardiac Arrhythmias and Treatments
- Medication Adherence and Compliance
- Cardiomyopathy and Myosin Studies
- Atrial Fibrillation Management and Outcomes
- Parathyroid Disorders and Treatments
- Nutrition and Health in Aging
- Pericarditis and Cardiac Tamponade
- Hormonal Regulation and Hypertension
- Cardiovascular Health and Disease Prevention
- Cardiac Imaging and Diagnostics
- Epilepsy research and treatment
- Atherosclerosis and Cardiovascular Diseases
- Cardiac, Anesthesia and Surgical Outcomes
- Congenital Heart Disease Studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac Arrest and Resuscitation
Karolinska Institutet
2023-2025
Stockholm South General Hospital
2025
University Hospital of Zurich
2018-2021
Zurich Heart House
2020
University of Brescia
2011-2018
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2016
Fondazione Poliambulanza Istituto Ospedaliero
2016
The aim of this analysis was to provide data on the overall comorbidity burden, both cardiovascular (CV) and non-CV, in a large real-world heart failure (HF) population across ejection fraction (EF).
BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study assessed rates of, patient profiles, associations morbidity/mortality renin-angiotensin inhibitors (RASi), angiotensin receptor–neprilysin (ARNi), beta-blockers (BBL), mineralocorticoid receptor antagonists (MRA) withdrawal HF EF. METHODS: Patients a first recorded EF <40% later ≥40% from Swedish...
ABSTRACT Aims Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart failure with reduced ejection fraction (HFrEF) but remain underused and are often discontinued especially patients chronic kidney disease (CKD) due to concerns on renal safety. Therefore, a real‐world HFrEF population we investigated the safety of MRA use, terms risk events, any mortality hospitalization, across estimated glomerular filtration rate (eGFR) spectrum including severe CKD. Methods results We...
The Heart Failure Association of the European Society Cardiology has recently proposed to optimize guideline-directed medical treatments according patient's profiles. aim this analysis was investigate prevalence/characteristics/treatments/outcomes for individual profiles.Patients with heart failure (HF) reduced ejection fraction (HFrEF) enrolled in Swedish Registry (SwedeHF) between 2013 and 2021 were considered. Among 108 profiles generated by combining different strata renal function (by...
Amino acids (AAs) availability is reduced in patients with heart failure (HF) leading to abnormalities cardiac and skeletal muscle metabolism, eventually a reduction functional capacity quality of life. In this study, we investigate the effects oral supplementation essential semi-essential AAs for three months stable chronic HF. The primary endpoints were AA's on exercise tolerance (evaluated by cardiopulmonary stress test six minutes walking (6MWT)), whether secondary change life Minnesota...
Abstract Aims Heart failure (HF) and atrial fibrillation (AF) often coexist. We explored AF incidence, prevalence, treatment strategies in patients with versus without HF across the ejection fraction (EF) spectrum. Methods results analysed from Swedish Registry (1 December 2005–31 2021), matched 1:1 by sex, age, county of residence to Statistics Sweden. Two study cohorts were derived (i) assess prevalence treatments, (ii) evaluate incidence related predictors. Overall, 195 106 considered,...
Abstract Aims Heart failure (HF) with preserved ejection fraction (HFpEF) is characterized by growing incidence and poor outcomes. A large majority of HFpEF patients are cared non‐cardiologists. The availability sodium–glucose cotransporter 2 inhibitors (SGLT2i) as recommended therapy raises the importance prompt accurate identification treatment across diverse healthcare settings. We evaluated management specialties through a survey targeting cardiologists, HF specialists, Methods results...
Abstract Background Guideline-directed medical therapy reduces mortality/morbidity in heart failure (HF) with reduced ejection fraction (EF). However, evidence about its use and prognostic role once EF has improved is limited. Purpose To assess associations of renin-angiotensin system inhibitors (RASi), angiotensin-receptor neprilysin (ARNi), beta-blockers (BBL), mineralocorticoid receptor antagonists (MRA) patients HF (HFimpEF). Methods We analyzed HFimpEF, defined as a first recorded...
<b>Background:</b> Chronic obstructive pulmonary disease (COPD) and aortic stenosis (AS) are common well-recognised causes of morbidity mortality. These conditions studied separately while their interplay entails significant implications. COPD its severity may influence valve replacement decision in symptomatic AS patients needing invasive treatment: confound symptoms obstruction, is part the risk scores for predicting cardiac surgery mortality one main reasons denial. The aim was to examine...
Heart failure is the leading cause of death and hospitalization in industrialized countries a major healthcare costs. It associated with severe symptoms its prognosis remains poor. Further improvement needed beyond results pharmacological treatment devices. The role nutrition has therefore been studied both early stages heart failure, as tool for reduction cardiovascular risk factors symptomatic prevention congestion fluid overload. In addition, dietary supplements, such n-3 polyunsaturated...
<h3>Introduction and Objectives</h3> COPD is associated with increased prevalence of cardiovascular comorbidities mortality from cardiac pathologies. In heart valve diseases, the onset dyspnoea main determinant outcome treatment. Thus, may represent a confounding factor in patients severe aortic stenosis (AS) whilst influencing management. Moreover, correct diagnosis symptomatic AS extremely challenging. We investigate its relation all-cause mortality. <h3>Methods</h3> Consecutive referred...
<b>Background:</b> COPD identification may impact symptomatic aortic stenosis (AS) patients in whom is one of the main reasons for cardiac treatment delay/exclusion. The prognostic role lung disease defined by Society Thoracic Surgeon (STS) criteria was previously shown. However, COPD-STS can be based on therapy alone and reflect long-standing dyspnoea rather than AS. <b>Purpose:</b> To assess prevalence all-cause mortality relationship Methods: Multi-centre retrospective study severe AS...